MedTrace Logo

Exosome-based Liquid Biopsies for Upper Gastrointestinal Cancers Diagnosis

NCT06278064 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 562

Last updated 2024-02-26

No results posted yet for this study

Summary

This study constitutes a case-control investigation employing a retrospective approach. Plasma samples from individuals with esophageal cancer, benign esophageal diseases, gastric cancer, benign gastric diseases, and a healthy control group were systematically collected. Advanced Data-Independent Acquisition (DIA) proteomics and single-vesicle membrane protein detection techniques were employed to quantify protein content within exosomes. Specific protein biomarkers indicative of early-stage upper gastrointestinal tumors were identified. External validation of these protein markers was conducted using Parallel Reaction Monitoring (PRM) technology on an independent validation cohort. The objective is to establish protein marker predictions for early diagnosis of upper gastrointestinal tumors and prognostication of therapeutic efficacy.

Conditions

Interventions

OTHER

Gastric Cancer

Patients diagnosed with gastric cancer, including early stage gastric and advanced gastric cancer

OTHER

Esophagus Cancer

Patients diagnosed with esophagus cancer, including early esophagus gastric and advanced esophagus cancer

Sponsors & Collaborators

  • Beijing Friendship Hospital

    lead OTHER

Principal Investigators

  • Li Min, Ph.D. · Beijing Friendship Hospital

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2024-12-31
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06278064 on ClinicalTrials.gov